US Targets China Biotech with New Outbound Investment Restrictions to Block Capital and IP Access

The Great Decoupling: How U.S. Biotech Strategy is Rewriting Global Pharma Rules

For decades, the global pharmaceutical industry operated under the assumption that scientific innovation knew no borders. But the winds are shifting. The U.S. Government is no longer just watching from the sidelines; it is actively moving to sever the financial and intellectual arteries connecting American capital to the Chinese biotech sector.

This isn’t just about trade tariffs anymore. It is a fundamental pivot toward “biosecurity sovereignty,” where the flow of dollars, patents, and proprietary research is being treated with the same national security rigor as military intelligence.

From Supply Chains to Capital Controls

While the initial focus of the U.S. Was on restricting hardware and supply chains—symbolized by the Biosecure Act—the new frontier is far more aggressive. Washington is now targeting the “outbound investment” pipeline.

Legislators are pushing to include biotechnology under the Comprehensive Outbound Investment National Security (COINS) Act. The goal is simple: stop U.S. Venture capital and private equity from fueling the rise of Chinese drug discovery platforms. By restricting the transfer of intellectual property (IP) and manufacturing know-how, the U.S. Aims to prevent its own innovation ecosystem from inadvertently subsidizing its primary geopolitical competitor.

Did you know? In 2020, the share of large-scale, cross-border pharmaceutical licensing deals involving Chinese firms was essentially zero. By last year, that figure had skyrocketed to nearly 48% of all global deals worth over $50 million.

The “Megaton” Partnership Problem

The alarm bells in Washington were triggered by the sheer scale of recent deals. Take, for instance, the partnership between Bristol Myers Squibb (BMS) and China’s Hengrui Medicine. With a potential valuation of up to $15.2 billion, these deals are no longer just licensing agreements; they are deep-tissue integrations of research and development.

U.S. Officials argue that these joint ventures often involve early-stage molecular research. When that research happens in Chinese labs—or worse, in facilities with ties to the Chinese military—the risk of data leakage and the transfer of proprietary “secret sauce” becomes an existential threat to American competitiveness.

Why Clinical Data Security is the New Battlefield

Beyond the money, there is a growing concern over the ethics of clinical trials. Reports suggesting that sensitive medical data collected in Chinese hospitals—potentially involving vulnerable populations or military-affiliated institutions—could be harvested for state purposes have turned the industry upside down.

The BIOSECURE Act will put in motion US government-wide restrictions… #pharmanews #biotechnews

For global pharmaceutical giants, the dilemma is clear: how do you maintain a global footprint while navigating a regulatory landscape that demands strict data compartmentalization? The risk of being “caught in the middle” of this U.S.-China tech war is now a boardroom priority.

What This Means for the Global Market

If the U.S. Moves forward with strict investment prohibitions, the ripple effects will be felt far beyond the U.S. And China:

Regional Realignments: Biotech hubs in South Korea, Japan, and parts of Europe may see a massive influx of capital as firms look for “neutral” ground to conduct R&D.
CDMO Shift: Contract Development and Manufacturing Organizations (CDMOs) outside of China are already seeing increased interest from Western firms looking to de-risk their supply chains.
Higher R&D Costs: Separating research ecosystems is inherently inefficient. Investors should expect short-term volatility as the industry adjusts to a bifurcated global market.

Pro Tip: Investors should look closely at firms that have diversified their manufacturing footprints across multiple continents. Companies that rely exclusively on single-source, cross-border partnerships are currently facing the highest regulatory risk.

Frequently Asked Questions

What is the COINS Act?: The Comprehensive Outbound Investment National Security Act is a proposed U.S. Framework designed to screen or block American capital from flowing into sensitive technology sectors in adversarial nations.
Why is the U.S. Targeting biotech specifically?: Biotech is viewed as a critical pillar of national security. The U.S. Fears that control over drug development and genomic data is just as vital as control over semiconductors or AI.
Will this affect drug prices for consumers?: While the goal is national security, the transition away from low-cost Chinese manufacturing could lead to higher R&D and production costs, which may eventually impact drug pricing.

Are you tracking how these regulatory shifts are impacting your portfolio or your company’s supply chain? Share your thoughts in the comments below, or subscribe to our industry briefing for weekly updates on the intersection of geopolitics and biotech.